{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T14:01:58Z","timestamp":1776693718376,"version":"3.51.2"},"reference-count":0,"publisher":"OAE Publishing Inc.","content-domain":{"domain":["oaepublish.com"],"crossmark-restriction":false},"short-container-title":["CDR"],"DOI":"10.20517\/cdr.2021.30","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:47:15Z","timestamp":1624520835000},"update-policy":"https:\/\/doi.org\/10.20517\/oae.crossmark.policy","source":"Crossref","is-referenced-by-count":2,"title":["Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment"],"prefix":"10.20517","author":[{"given":"John K.","family":"Cowell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianxiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8410","published-online":{"date-parts":[[2021]]},"container-title":["Cancer Drug Resistance"],"original-title":[],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T08:45:33Z","timestamp":1705567533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oaepublish.com\/articles\/cdr.2021.30"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":0,"URL":"https:\/\/doi.org\/10.20517\/cdr.2021.30","relation":{},"subject":[],"published":{"date-parts":[[2021]]}}}